Pfizer Builds On The Genedata Biopharma E2E Workflow Platform

Pfizer’s global R&D network generates extraordinary scientific insight, but operating across continents also creates complexity. As teams advanced biotherapeutic programs in inflammation, immunology, oncology, rare disease, and vaccines, critical data was accumulating in isolated systems. These gaps made it difficult for researchers to share results, follow workflows, or trace how each group contributed to the drug discovery process. More than 200 scientists across six sites needed a way to align their processes and bring their information into a unified structure. After recognizing that a build‑as‑you‑go solution couldn’t scale, the organization turned to the market in search of an enterprise platform capable of supporting every stage of large‑molecule research.

Explore how a central, purpose‑built data backbone can transform collaboration and efficiency across complex biological R&D environments.